Sign in to view content

Complications, Compliance, and 2-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage

Dennis M. Marcus, MD

Video
Published 2020

Related

Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023
Dropless Vitrectomy Surgery for Dense Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy; Efficacy and Safety Compared With Standard of Care
K. V. Chalam, MD, PhD, MBA, FRCS(C), FASRS
Annual Meeting Talks
2024
Primary Results for Protocol AB
Andrew N. Antoszyk, MD FASRS
Updates from the Field
2020

Category: Diabetic Retinopathy

See more